Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Mirobio - The Real Truth

Want Passive Income in a Bear Market? Check out This Biotech Stock

With the minutes of the latest Fed meeting showing that interest rates will keep increasing this year, the economy is widely expected to enter a recession. Amid the expected downturn this year, it could be wise to buy biotech stock Gilead Sciences (GILD) due to its solid growth prospects and…

StockNews.com

Up More than 19% In 2022, Is Gilead Sciences Still a Buy?

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

StockNews.com

GILD Stock: Is It Still a Smart Investment Ahead of 2023?

GILD gained prominence during the pandemic, but the company’s COVID-19 drug Veklury registered a decline in sales because of declining COVID-19 cases. However, it beat revenue and earnings estimates in the previous quarter. Will the company be able to record further growth in the coming year? Read more to learn…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks That'll Make You Richer and 1 That Won't

The biotech industry continues to stay resilient to broader economic challenges. Moreover, the planned multi-million-dollar government investments should bode well for the industry. Hence, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys to cash in on the industry’s prospects. However, fundamentally weak stock…

StockNews.com

It's Not Too Late for Investors to Start Buying GILD Stock

Biopharmaceutical giant Gilead Sciences (GILD) has delivered solid segmental sales growth in the last reported quarter. In addition, the company’s various research breakthroughs and drug approvals should further bolster its performance in the coming months. Given its robust profitability and discounted valuation, we think it could be wise to scoop…

StockNews.com

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

StockNews.com

3 High-Yield Dividend Stocks to Buy Right Now

Amid the persisting market volatility on concerns over high inflation and a looming recession, we think it could be wise to invest in fundamentally strong dividend-paying stocks Vodafone Group (VOD), Gilead Sciences (GILD), and BHP Group (BHP) for a steady income stream. Read more….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

People

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

Merck & Co., Inc.

51 stories

Jazz Pharmaceuticals plc

44 stories

VOD

33 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.